Abstract
Severe aplastic anemia (sAA) is a bone marrow failure disorder which is mostly a consequence of immunologically mediated stem cell destruction. Allogeneic bone marrow transplantation (BMT) from a compatible donor provides long-term survival in 60 to 80% of sAA patients. However, graft rejection still remains a major problem, and a second allograft is an alternative for these patients. We retrospectively analyzed 34 patients who received a second BMT (BMT2), nine with primary graft failure (PGF) and 25 with transient engraftment (TE). The probability of survival at 13 years among PGF patients was 22% vs 60% for the TE group (P = 0.0068). Age (<17 vs>17 years), number of mononuclear cells (<3 vs >3 × 108/kg) and year of transplant (1986–1991 vs 1992–1998) at BMT2 had no statistical influence on survival. A significant survival advantage was noted among TE patients (P = 0.0068), which was probably because of a longer intertransplant interval (>90 days). Furthermore, 90% of patients with positive blood cultures at BMT2 did not survive the procedure. We conclude that early detection of primary graft failure (PGF), followed by measures attempting to promote hematopoietic recovery (eg use of growth factors, further infusion of stem cells) may decrease mortality. Bone Marrow Transplantation (2001) 28, 941–944.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Young NS, Maciejewski J . Mechanism of disease: the pathophysiology of acquired aplastic anemia New Engl J Med 1997 336: 1365–1372
McCann SR, Bacigalupo A, Gluckman E et al. Graft rejection and second marrow transplants for acquired aplastic anemia: a report from the Aplastic Anemia Working Party of the European Marrow Transplant Group Bone Marrow Transplant 1994 13: 233–237
Stucki A, Leisenring W, Sandmaier BM et al. Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis) Blood 1998 92: 2742–2749
Passweg JR, Socie G, Hinterberger W et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997 90: 858–864
Bacigalupo A, Brand R, Oneto R et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy – The European Group for Blood and Marrow Transplantation Experience Semin Hematol 2000 37: 30–42
Storb R, Deeg HJ, Farewell W et al. Marrow transplantation for severe aplastic anemia: methotrexate and cyclosporin for prevention of acute graft-versus-host disease Blood 1986 68: 119–125
Champlin RE, Horowitz MM, vanBekkun DW et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results Blood 1989 73: 606–613
Young NS . Aplastic anemia Lancet 1995 346: 228–232
Storb R, Weiden PL, Sullivan KM et al. Second marrow transplant in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin Blood 1987 70: 116–121
Guardiola P, Kuentz M, Garban F et al. Second early allogeneic stem cell transplantation for graft failure in acute leukemia, chronic myeloid leukemia and aplastic anemia Br J Haematol 2000 111: 292–302
Bacigalupo A . Bone marrow transplantation for severe aplastic anemia from HLA-identical siblings Haematologica 1999 84: 2–4
Hows J, Palmer S, Gordon-Smith EC . Cyclosporine and graft failure following bone marrow transplantation for severeaplastic anemia Br J Haematol 1985 60: 611–617
Kojima S . Hematopoietic growth factors and marrow stroma in aplastic anemia Int J Hematol 1998 68: 19–28
Mehta J, Powles R, Singhal S et al. Early identification of patients at risk of death due to infections, hemorrhage or graft failure after allogeneic bone marrow transplantation on the basis of leukocyte counts Bone Marrow Transplant 1997 19: 349–355
Zecca M, Perotti C, Marradi P et al. Recombinant humanG-CSF mobilized peripheral blood stem cells for a second allogeneic transplant after bone marrow graft rejection in children Br J Haematol 1996 92: 432–434
Redei I, Waller EK, Holland HK et al. Successful engraftment after primary graft failure in aplastic anemia using G-CSF mobilized peripheral stem cell transfusions Bone Marrow Transplant 1997 19: 175–177
Acknowledgements
The authors are indebted to Miss Heliz RA Neves (Data Manager) for all the data analysis help.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Medeiros, C., Bitencourt, M., Medeiros, B. et al. Second bone marrow transplantation for severe aplastic anemia: analysis of 34 cases. Bone Marrow Transplant 28, 941–944 (2001). https://doi.org/10.1038/sj.bmt.1703257
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703257
Keywords
This article is cited by
-
Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia
Bone Marrow Transplantation (2015)
-
CD34-enriched peripheral stem cells infusion for graft insufficiency treatment in a pediatric patient with severe aplastic anemia after allogeneic bone marrow transplantation
Bone Marrow Transplantation (2004)